SCHEMBL7080195

SCHEMBL7080195

CCCCC(C(N)=O)C(=O)N1CCC(N2CCCC2)CC1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 3/20 0.41
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
L3MBTL3 Q96JM7 11/20 0.39
L3MBTL1 Q9Y468 10/20 0.39
MBTD1 Q05BQ5 5/20 0.39
TP53BP1 Q12888 3/20 0.39
L3MBTL4 Q8NA19 2/20 0.39
ALOX15 P16050 1/20 0.39
DPP8 Q6V1X1 2/20 0.38
DPP4 P27487 1/20 0.38
FAP Q12884 1/20 0.38
DPP9 Q86TI2 1/20 0.38
DPP7 Q9UHL4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7080188 1.00 CHRM1 (0.41) CHRM1CYP3A4CYP2C19L3MBTL3L3MBTL1
SCHEMBL13030971 0.82 DPP7 (0.50) CHRM1CYP3A4CYP2C19L3MBTL3L3MBTL1
SCHEMBL8498698 0.79 L3MBTL1 (0.47) L3MBTL1DPP7
SCHEMBL7070620 0.74 MMP1 (0.40) CHRM1CYP3A4CYP2C19L3MBTL3L3MBTL1
SCHEMBL7070617 0.74 MMP1 (0.40) CHRM1CYP3A4CYP2C19L3MBTL3L3MBTL1
SCHEMBL7065755 0.74 MMP1 (0.42) CHRM1CYP3A4CYP2C19L3MBTL3L3MBTL1
SCHEMBL15045187 0.71 CYP3A4 (0.50) CHRM1CYP3A4CYP2C19L3MBTL3L3MBTL1
SCHEMBL18251701 0.71 CYP3A4 (0.52) CHRM1CYP3A4CYP2C19L3MBTL3L3MBTL1
SCHEMBL12396446 0.70 CYP3A4 (0.55) CHRM1CYP3A4CYP2C19L3MBTL3L3MBTL1
SCHEMBL1334264 0.69 MEN1 (0.68) L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268454-A1 SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2003-01-02 EP disclosed
WO-2001074796-A1 SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-10-11 WO disclosed